Business Context and Reporting Period
Company: Brainsway Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended June 30, 2025
Business Overview: Brainsway is a global leader in non-invasive neurostimulation treatments for mental health disorders using its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform. The company holds FDA clearances for Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), and smoking addiction. As of June 30, 2025, the installed base of Deep TMS systems reached approximately 1,522 units.
Key Financial Metrics
| Metric (in thousands USD) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenues | $24,168 | $19,100 |
| Gross Profit | $18,109 | $14,349 |
| Gross Margin | 74.9% | 75.1% |
| Operating Profit | $1,154 | $679 |
| Net Profit | $3,134 | $711 |
| Diluted EPS | $0.07 | $0.02 |
| Cash and Cash Equivalents | $67,912 | $47,864 |
| Total Current Assets | $89,031 | $79,670 |
| Total Current Liabilities | $25,508 | $15,346 |
| Net Cash from Operating Activities | $17,393 | $4,526 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 27% to $24.2 million, driven by a shift in mix toward sales (64% of revenue) compared to leases (24%), whereas the prior period was more lease-heavy (48%).
- Profitability Surge: Net profit increased 341% to $3.1 million. This was significantly aided by a $2.2 million net finance income, largely due to favorable foreign exchange movements and interest income, compared to $0.3 million in the prior year.
- Expense Increases: Operating expenses rose 24% to $17.0 million. Research and Development (R&D) expenses increased 42% due to higher headcount and clinical trial investments. Selling and marketing expenses rose 20% due to commercial team expansion in the U.S.
- Deferred Revenue: Deferred revenues increased significantly from $8.1 million (total) at year-end 2024 to $22.7 million at June 30, 2025, reflecting strong upfront cash collections from customers.
Outlook, Risks, and Unusual Items
Strategic Investments and Subsequent Events
- Stella MSO: Invested $5.0 million in June 2025 for a minority stake in a mental health clinic management services organization.
- Neurolief Ltd.: In August 2025, provided a $5.0 million convertible loan with an option to acquire the developer of a wearable neuromodulation platform. Additional milestone funding up to $11.0 million is possible.
- Axis Integrated Mental Health: In August 2025, invested $2.3 million for approximately 30% equity in a Colorado-based mental health clinic management organization.
Risks and Contingencies
- Tariff Exposure: The filing notes a 17% reciprocal tariff on goods imported from Israel to the U.S. announced in April 2025. While the company does not believe H1 2025 results were materially affected, future U.S. sales could be impacted if tariffs remain.
- Warrant Reclassification: A warrant liability of $2.4 million was reclassified to equity in April 2025 following an amendment to the terms (removal of cashless exercise feature), eliminating the liability from the balance sheet.
- Liquidity: Management believes existing cash resources ($78.3 million including short-term deposits) are sufficient to fund operations in the foreseeable future.
Investor Verification Checklist
- Revenue Mix Sustainability: Verify if the shift from lease-based to sales-based revenue is sustainable or a one-time spike, as this impacts future recurring revenue streams.
- Non-Operating Income Reliance: Assess the extent to which net profit relies on finance income (currency gains and interest) rather than core operating margins.
- Tariff Impact: Monitor the company's strategy to mitigate the 17% U.S. tariff on Israeli goods and its potential effect on pricing and demand.
- Capital Allocation: Review the terms and potential dilution or cash outflow risks associated with the new strategic investments in Stella, Neurolief, and Axis.
- Deferred Revenue Recognition: Track the rate at which the $22.7 million in deferred revenue is recognized to ensure it aligns with future revenue guidance.